| IFNL4 Genotype for Predicting Response to Ledipasvir/Sofosbuvir (NCT03639207) | National Cancer Institute (NCI) | 2018-06-15 |
| Simplified Antiviral Treatment Strategy for Hepatitis C in Ukraine (NCT04038320) | Right to Care | 2018-03-26 |
| Harvoni in Patients With Chronic Hepatitis C Virus (HCV) Infection in Korea (NCT02951364) | Gilead Sciences | 2016-12-05 |
| Evaluate the Safety and Effectiveness of Sovaldi in Participants With Chronic Hepatitis C Virus (HCV) Infection in Korea (NCT02907996) | Gilead Sciences | 2016-09-09 |
| HCV Care Pathway in Ile-de-France (NCT02893046) | Assistance Publique - Hôpitaux de Paris | 2016-09-01 |
| A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2) (NCT02692703) | AbbVie | 2016-04-22 |
| Study to Describe the Actual Situation of Hepatitis C Treatment in Brazil (NCT02773394) | Janssen-Cilag Ltd. | 2016-04-12 |
| A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection (NCT02723084) | AbbVie | 2016-04-08 |
| An Observational/Non-interventional, Study of NS3/4a Protease and NS5A Protein of Hepatitis C Virus in Brazilian Participants With Chronic HCV Infection (NCT02597270) | Janssen-Cilag Ltd. | 2016-03-01 |
| A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection (NCT02707952) | AbbVie | 2016-02-22 |
| The Durability of Response and Persistence of Resistance to AbbVie's 2 Direct-acting Antiviral Agent (2D) Therapy in Japanese Subjects (NCT02581020) | AbbVie | 2016-01-14 |
| A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection (NCT02640157) | AbbVie | 2015-12-01 |
| Safety and Efficacy of Sofosbuvir-based Regimens in Clinical Practice for the Treatment of Chronic Hepatitis C Virus Infection in India (NCT02592057) | Gilead Sciences | 2015-11-30 |
| A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults (NCT02582632) | AbbVie | 2015-11-24 |
| The Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 4, 5, or 6 Infection (ENDURANCE-4) (NCT02636595) | AbbVie | 2015-11-01 |
| A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection (NCT02604017) | AbbVie | 2015-10-01 |
| Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV Treatment (NCT02460133) | Nova Scotia Health Authority | 2015-07-10 |
| A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection (NCT02442284) | AbbVie | 2015-05-13 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy (NCT02446717) | AbbVie | 2015-04-01 |
| A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis (NCT02219477) | AbbVie | 2014-11-24 |
| A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1) (NCT02265237) | AbbVie | 2014-10-28 |
| Japanese Bridging Study Conducted in the United States (NCT00947245) | Bristol-Myers Squibb | 2014-10-01 |
| Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease (NCT02207088) | AbbVie | 2014-09-23 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection (NCT02243293) | AbbVie | 2014-09-19 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With HCV Genotype 1, 4, 5, and 6 Infection (NCT02243280) | AbbVie | 2014-08-01 |
| Two-way Interaction Between Alisporivir and EDP239 (NCT02173574) | Enanta Pharmaceuticals, Inc | 2014-08-01 |
| A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1 (NCT02170727) | Bristol-Myers Squibb | 2014-06-26 |
| Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin in Participants With Chronic Hepatitis C Who Failed Prior Direct-Acting Antiviral Therapy (MK-5172-048) (NCT02105454) | Merck Sharp & Dohme LLC | 2014-05-23 |
| A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and ABT-530 Coadministered With and Without Ribavirin in Adults With Genotype 3 Hepatitis C (HCV) Infection (NCT02068222) | AbbVie | 2014-04-01 |
| Safety and Efficacy of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052) (NCT02092350) | Merck Sharp & Dohme LLC | 2014-03-17 |
| Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection (NCT02073656) | Gilead Sciences | 2014-02-01 |
| A Study to Examine Patient Characteristics, Health Care Management and Health Outcomes of Hepatitis C Virus (HCV) Patients Treated With Simeprevir (NCT02103699) | Janssen Scientific Affairs, LLC | 2014-02-01 |
| Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT- 267 (ABT-450/r/ABT-267) in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection (NCT02023112) | AbbVie | 2014-01-01 |
| "Pharmacoepidemiological Evaluation of Autophagy Inhibition in Treatment of HCV Patients Resistant to Standard Therapy. Pilot Study" (NCT02058173) | Shiraz University of Medical Sciences | 2014-01-01 |
| A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV) (NCT01995071) | AbbVie | 2013-11-01 |
| Assessment of Intrahepatic Hepatitis C Virus (HCV) RNA Levels at the Time of Liver Transplantation (NCT01836718) | Schiano, Thomas D., MD | 2013-06-01 |
| Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia (NCT01741545) | Bristol-Myers Squibb | 2013-03-31 |
| Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C (NCT01629732) | Bristol-Myers Squibb | 2013-03-01 |
| Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection (NCT01838590) | Gilead Sciences | 2013-03-01 |
| Sofosbuvir Plus Ribavirin in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection (NCT01713283) | Gilead Sciences | 2012-10-01 |
| Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus (NCT01628692) | Bristol-Myers Squibb | 2012-07-01 |
| Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir (NCT01598090) | Bristol-Myers Squibb | 2012-06-14 |
| Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials) (NCT01573351) | Bristol-Myers Squibb | 2012-05-01 |
| Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives) (NCT01581203) | Bristol-Myers Squibb | 2012-05-01 |
| A Study in Healthy Female Participants Investigating the Effect of TMC435 on the Pharmacokinetics of the Synthetic Hormones of the Oral Contraceptive Ovysmen (NCT01486004) | Tibotec Pharmaceuticals, Ireland | 2011-11-01 |
| A Study in Healthy Participants Investigating the Effect of TMC435 on the Pharmacokinetics of Immunosuppressants Cyclosporine and Tacrolimus (NCT01479881) | Tibotec Pharmaceuticals, Ireland | 2011-10-01 |
| A Study to Evaluate Paritaprevir With Ritonavir (ABT-450/r) When Given Together With Ombitasvir and With and Without Ribavirin (RBV) in Treatment-Naïve Participants With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV) (NCT01458535) | AbbVie (prior sponsor, Abbott) | 2011-09-01 |
| A Study to Evaluate the Pharmacokinetic Effect of SCH 503034 (Boceprevir) on Methadone or Buprenorphine/Naloxone Plasma Concentrations (P08123) (NCT01396005) | Merck Sharp & Dohme LLC | 2011-09-01 |
| TMC435-TiDP16-C126 - Trial to Investigate the Effect of Severe Renal Impairment on the Pharmacokinetics and Safety of TMC435 (NCT01381835) | Tibotec Pharmaceuticals, Ireland | 2011-07-01 |
| TMC649128HPC1002 - a Trial inGenotype 1 Hepatitis C Virus (HCV) - Infected Participants to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of TMC649128, Alone and Combined With Pegylated Interferon + Ribavirin (NCT01391117) | Tibotec BVBA | 2011-06-01 |
| TMC435-TiDP16-C115 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and Erythromycin and Between TMC435 and Darunavir/Ritonavir (DRV/r) (NCT01323257) | Tibotec Pharmaceuticals, Ireland | 2011-03-01 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (NCT01306617) | AbbVie (prior sponsor, Abbott) | 2011-02-01 |
| TMC435-TiDP16-C108 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and Digoxin and Between TMC435 and Rosuvastatin (NCT01288742) | Tibotec Pharmaceuticals, Ireland | 2011-01-01 |
| Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection (NCT01257204) | Bristol-Myers Squibb | 2010-12-01 |
| Ph IIA Study (SOC +/- NS5B) (NCT01193361) | Bristol-Myers Squibb | 2010-10-01 |
| TMC435-TiDP16-C123 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and the Antiretroviral Agents Efavirenz and Raltegravir (NCT01241773) | Tibotec Pharmaceuticals, Ireland | 2010-10-01 |
| Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment (NCT01170962) | Bristol-Myers Squibb | 2010-08-01 |
| Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients (NCT01188772) | Gilead Sciences | 2010-08-01 |
| TMC435-TiDP16-C125 - Study in Healthy Volunteers to Evaluate the Potential of TMC435 to Increase the Sensitivity of the Skin Towards Exposure to Sun Light (NCT01124799) | Tibotec Pharmaceuticals, Ireland | 2010-07-01 |
| TMC435-TiDP16-C119 - A Study Comparing 2 New Capsule Formulations of TMC435 to an Established Capsule Formulation and Evaluating the Respective Blood Levels of TMC435 Following Single Dose Administration (NCT01134718) | Tibotec Pharmaceuticals, Ireland | 2010-06-01 |
| TMC435-TiDP16-C112 - Interaction Trial With Antidepressants (NCT01090700) | Tibotec Pharmaceuticals, Ireland | 2010-05-01 |
| Concentration-Controlled Ribavirin for the Treatment of Patients With Chronic Hepatitis C Virus Infection (NCT01097395) | University of Colorado, Denver | 2010-02-01 |
| A Pilot Trial to Determine the Safety and Efficacy of Fluvastatin in Previous Partial Responders to Pegylated Interferon and Ribivirin in Patients With Genotype 1 Hepatitis C (NCT00814606) | University of Chicago | 2010-02-01 |
| Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin (NCT01030432) | Bristol-Myers Squibb | 2010-02-01 |
| TMC435-TiDP16-C121: A Study Comparing 2 Tablet Formulations of TMC435 to an Established Capsule Formulation and Evaluating the Effect of Food on Blood Levels of TMC435 (NCT01022125) | Tibotec Pharmaceuticals, Ireland | 2010-01-01 |
| TMC435-TiDP16-C113: A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of TMC435 (NCT01046058) | Tibotec Pharmaceuticals, Ireland | 2010-01-01 |
| Drug Interaction Oral Contraceptive Pill (OCP) (NCT01063023) | Bristol-Myers Squibb | 2010-01-01 |
| Pilot Study to Assess Gut Mucosal B Cells in Individuals With HCV and HIV (NCT01040039) | Rockefeller University | 2009-11-01 |
| Retreatment With High Doses of pegIFN Alfa-2a and Ribavirin of Previous Nonresponders HIV-coinfected Patients With Cirrhosis Due to HCV 1-4 (NCT01006031) | Sociedad Andaluza de Enfermedades Infecciosas | 2009-10-01 |
| Magnetic Resonance Elastography for Assessment of Liver Fibrosis (MK-0000-132)(COMPLETED) (NCT00896233) | Merck Sharp & Dohme LLC | 2009-08-01 |
| A Pilot Study of the Grapefruit Flavonoid Naringenin for HCV Infection (NCT01091077) | Massachusetts General Hospital | 2009-06-01 |
| Trends in Risk Factors for Mother-to-Child Transmission of Hepatitis C Among a Southern European Population (NCT00894257) | Centre Hospitalier Universitaire de Nice | 2009-05-25 |
| Bioavailability Study Of PF-00868554 Administered As 3x250mg Oral Tablets (Wet Granulate, 3x250mg Oral Tablets (Dry Granulate) And 750mg Solution Under Fed State (NCT00861458) | Pfizer | 2009-04-01 |
| Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04878691 (NCT00810758) | Pfizer | 2009-01-01 |
| Observational Trial of Hepatitis C Virus Infected Patients on Calcineurin Inhibitors (NCT00819026) | University of Wisconsin, Madison | 2008-10-01 |
| Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures (NCT00678587) | GlaxoSmithKline | 2008-06-01 |
| Effect of Insulin Resistance on the Safety and Efficacy of Pegylated Interferon and Ribavirin Treatment in HCV (Study P05562) (NCT00705224) | Merck Sharp & Dohme LLC | 2008-05-01 |
| Phase 1 Study To Evaluate Antiviral Activity Of Small Molecule Direct Antiviral Agent At Multiple Doses In Subjects With Chronically Infected Hepatitis C Virus. (NCT00671671) | Pfizer | 2008-04-01 |
| Adaptive Phase I HCV Study With Nucleoside Analogue, in Combination With Interferon and Ribavirin (NCT00382798) | Pharmasset | 2006-10-01 |
| Different PEG-interferon and Ribavirin Schedules for Chronic Hepatitis C in the Real Clinical Practice. (NCT01195181) | Azienda Ospedaliera di Padova | 2005-09-01 |
| Association Between Hepatitis C Virus Infection and Hematologic and Thyroid Cancers (NCT00342641) | National Cancer Institute (NCI) | 2005-06-08 |
| Assessment of Biomarkers for Recurrent HCV Infection Post-liver Transplantation (NCT00710801) | University of Alberta | 2005-05-01 |
| PEG-IFN Plus Ribavirin Combination Therapy for Older Patients (NCT00956982) | Kyushu University | 2004-12-01 |
| Multicenter Study Evaluating 12 Versus 24 Weeks Therapy With Peginterferon and Ribavirin for Hepatitis C Virus (HCV) Genotype 2 or 3 (NCT00143000) | NORDynamIC Study Group | 2004-04-01 |
| Treatment of Anemia and Neutropenia in HIV/HCV Coinfected Patients Treated With Pegylated Interferon and Ribavirin (NCT00194857) | Weill Medical College of Cornell University | 2002-02-01 |
| Hepatitis C Virus and the Humoral Immune System (NCT00219999) | Rockefeller University | 2001-09-01 |
| Study of Long-term Peg Intron vs. Colchicine in Non-responders. (NCT00179413) | Beth Israel Deaconess Medical Center | 2000-01-15 |
| Effects of Sho-saiko-to, a Herbal Formula, in Reducing Viral Load in Hepatitis C (NCT00633230) | University of Virginia | |